Remember that There Are at Least Seven Modalities for Treating Hyperkalemia in the Perioperative Period
Grace L. Chien MD
Hyperkalemia means that serum potassium levels are elevated beyond normal levels (the upper limit is usually reported as 5 to 5.5 mmol/L). Hyperkalemia has few clinical manifestations. In awake patients, severe muscle weakness beginning with the lower extremities and progressing cephalad, usually sparing cranial nerves and respiratory muscles, is sometimes evident. In patients under general anesthesia, the primary abnormality manifests as electrocardiogram (EKG) changes starting with peaked T waves, shortened QT interval, progressive lengthening of the PR interval, and QRS duration. The P wave may disappear, and ultimately, wide, complex ventricular tachycardia presents, eventually progressing to ventricular standstill. Hyperkalemia may also cause a variety of heart blocks, including bundle branch block and atrioventricular (AV) blocks. The manifestations of hyperkalemia depend on the rate of potassium rise—they are better tolerated by patients with chronic hyperkalemia. EKG changes with hyperkalemia are affected by concomitant hypocalcemia, academia, and hyponatremia.
PATHOGENESIS OF HYPERKALEMIA
Although hyperkalemia has many etiologies (Table 74.1), there are three distinct pathways: (i) ineffective elimination of potassium during any interval in the perioperative period, almost always due to renal failure; (ii) acute potassium load from a medication error or massive transfusion of stored blood; (iii) movement of potassium ions from the intracellular space to the extracellular space. This last can occur with the use of succinylcholine, especially for burn patients or paralyzed patients. It can also be seen with changes in ventilation and/or acid-base status in patients on certain drug combinations (spironolactone/beta-blockers) or significant physiologic derangements such as diabetic ketoacidosis. At the cellular level, hyperkalemia interferes with neuromuscular transmission and thus produces skeletal and cardiac muscle abnormalities. Neuromuscular transmission depends on membrane excitability. Increased extracellular potassium depolarizes the cell membrane, making the cell more excitable, and requiring less of a stimulus to generate an action potential. The hyperexcitability eventually
inactivates sodium channels and leads to cardiac conduction abnormalities and muscle paralysis.
inactivates sodium channels and leads to cardiac conduction abnormalities and muscle paralysis.
TABLE 74.1 DISORDERS THAT CAUSE HYPERKALEMIA | ||||
---|---|---|---|---|
|
TREATMENT OF HYPERKALEMIA
A valuable resource is the Cochrane Database of Systematic Reviews, which has published recommendations for emergency interventions for hyperkalemia. Current evidence suggests that intravenous (IV) insulin and glucose combined with nebulized beta-adrenergic receptor agonists were more effective than each treatment alone.
Calcium.
Calcium stabilizes cardiac muscle and directly antagonizes the hyperexcitability induced by hyperkalemia. Calcium starts acting within minutes and can be used as an infusion over 2 to 3 minutes. The dose is 500 mg to 1 g and may be repeated after 5 minutes. Calcium should not be given with bicarbonate, as calcium carbonate will precipitate. Patients who are taking digitalis are more vulnerable to toxicity with hypercalcemia, so calcium should be used with great caution in these patients.